Integumen PLC Rinocloud subsidiary wins "One To Watch" IT award
21 October 2019 - 5:00PM
RNS Non-Regulatory
TIDMSKIN
Integumen PLC
21 October 2019
AIM share code: SKIN
21 October 2019
Integumen PLC
("Integumen" or "Company")
Integumen's Rinocloud subsidiary wins "One To Watch" IT
award
Rinocloud, a wholly-owned subsidiary of Integumen, has won the
TechLeaders19 IT award, sponsored by KPMG in the "One To Watch"
category, at the Gala dinner in Cork, Ireland on Friday the 18th of
October.
The Tech Leaders awards, which are in their 13th year, shine a
light on those people who are leading the charge for the technology
community and paving the way for the continued success of the
technology sector in Ireland.
Fin Murray MD of Rinocloud and Executive Director of Integumen
commented:
"We are so honoured to have received this IT Leadership award in
recognition of the Rinocloud team's creation of a disruptive drug
discovery process for skin diseases such as psoriasis, eczema, acne
and dandruff.
We wouldn't have been able to do it without the support from
partner scientific research institutes APC Microbiome at the
University College Cork, and the Centre for Advanced Photonics
& Process Analysis at the Cork Institute of Technology, with
state support from Enterprise Ireland who was an early investor in
Rinocloud. We look forward to using our Rinocloud technology
platform to help our clients advance their work in developing
superior skin products and treatments."
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Vassil
(Nominated Adviser) Kirtchev +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments Andy Thacker/Zoe
(TPI) Limited (Broker) Alexander +44 (0) 20 3657 0050
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated product and services
company for skin related diseases, treatments and therapies with
three business units:
-- Labskin AI's technology platform incorporates artificial
intelligence within clinical research for medical device,
pharmaceuticals, cosmeceuticals and related life science test
services. Labskin allows skincare, healthcare, pharmaceutical
manufacturers and cosmetic companies to test their products on
human-like skin in a real-world environment with full access to
multiple state-of-the-art partner technologies.
-- Wound pHase is developing skin and wound care products using
its proprietary wound dressing technology. Working in collaboration
with CBD providers creating a CBD infused diabetic wound care
product range.
Stoer-for-men skin products e-commerce division offers a range
of skincare products derived from 5 natural super-ingredient plant
extracts specifically for men to reduce the signs of ageing and is
also used as a control for client testing within Labskin
laboratories.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKCDQBBDDQKD
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024